Inhibition of the fibrillation of highly amyloidogenic human calcitonin by cucurbit[7]uril with improved bioactivity
Source abstract
Abstract
Protein/peptide fibrillation is an important challenge for biotechnological drug development. Salmon calcitonin (sCT) is currently used in the clinical treatment of bone-related diseases such as osteoporosis and hypercalcemia, but it still has the risk of immune responses. Although human calcitonin (hCT) would be a better choice in terms of immunogenicity, it has a strong tendency to irreversibly aggregate in aqueous solutions and form long amyloid fibrils, which significantly reduces its bioavailability and therapeutic potency. Here, we demonstrate that cucurbit[7]uril (CB[7]) can inhibit hCT fibrillation by supramolecular interaction with its aromatic groups (affinity: Phe16 > Tyr12 > Phe19 > Phe22). The hCT-CB[7] complex exhibits low cytotoxicity, even promotes osteoblast proliferation and osteogenic capacity of MC3T3 cells. Meanwhile the hCT-CB[7] complexes shows higher bioactivity compared to hCT in reducing blood calcium levels in rats, and also decreases the immunogenicity of hCT. These results suggest that CB[7] has the potential to improve the therapeutic potency of amyloidogenic protein/peptide drugs such as hCT.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Crystallography and molecular interactions · RNA and protein synthesis mechanisms · Protein Structure and Dynamics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Protein aggregation—pathways and influencing factors10.1016/j.ijpharm.2010.02.025 ↗
2. Structure of the cross-beta spine of amyloid-like fibrils10.1038/nature03680 ↗
3. Protein misfolding, functional amyloid, and human disease10.1146/annurev.biochem.75.101304.123901 ↗
4. Review: modulating factors in amyloid-beta fibril formation10.1006/jsbi.2000.4289 ↗
5. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases10.1038/416507a ↗
6. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution10.1007/s00109-003-0464-5 ↗
7. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis10.1126/science.1079469 ↗
8. On the structural definition of amyloid fibrils and other polypeptide aggregates10.1007/s00018-007-7110-2 ↗
9. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis10.1210/er.2007-0037 ↗
10. Calcitonin-like immunoreactivity of amyloid fibrils in medullary thyroid carcinomas10.1007/BF00844290 ↗
11. Pathophysiology and treatment of systemic amyloidosis10.1038/nrneph.2013.171 ↗
12. Structure-immunogenicity relationships of therapeutic proteins10.1023/B:PHAM.0000029275.41323.a6 ↗
13. Effects of protein aggregates: an immunologic perspective10.1208/aapsj080359 ↗
14. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response10.1016/j.pneurobio.2011.10.001 ↗
15. Immunogenicity of therapeutic proteins: clinical implications and future prospects10.1016/S0149-2918(02)80075-3 ↗
16. Supramolecular nanoparticles of calcitonin and dipeptide for long-term controlled release10.1016/j.jconrel.2017.04.014 ↗
17. An evaluation of antibodies and clinical resistance to salmon calcitonin10.1172/JCI107044 ↗
18. Amino acid sequence of salmon ultimo branchial calcitonin10.1073/pnas.64.2.771 ↗
19. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis10.1007/BF01880446 ↗
20. Calcitonin - a review of experimental and clinical investigations10.1136/pgmj.44.511.411 ↗
21. Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin10.1074/jbc.M206039200 ↗
22. NMR characterization of monomeric and oligomeric conformations of human calcitonin and its interaction with EGCG10.1016/j.jmb.2011.12.023 ↗
23. Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-amyloidogenic analogue10.1074/jbc.M110.182014 ↗
24. Specific mutations alter fibrillation kinetics, fiber morphologies, and membrane interactions of pentapeptides derived from human calcitonin10.1021/bi1002713 ↗
25. Enhanced physical stability of human calcitonin after methionine oxidation10.1016/j.ejpb.2010.12.038 ↗
26. The cucurbit[n]uril family10.1002/anie.200460675 ↗
27. Molecular recognition of insulin by a synthetic receptor10.1021/ja201581x ↗
28. Supramolecular enhancement of protein analysis via the recognition of phenylalanine with cucurbit[7]uril10.1021/jacs.5b10648 ↗
29. Sequence recognition and self-sorting of a dipeptide by cucurbit[6]uril and cucurbit[7]uril10.1039/b719902c ↗
30. Cucurbituril-based molecular recognition10.1021/acs.chemrev.5b00341 ↗
31. Supramolecular amphiphiles based on host-guest molecular recognition motifs10.1021/cr5005315 ↗
32. Protein recognition using synthetic small-molecular binders toward optical protein sensing in vitro and in live cells10.1039/C4CS00381K ↗
33. Supramolecular inhibition of amyloid fibrillation by cucurbit[7]uril10.1002/anie.201402496 ↗
34. Cucurbit[7]-assisted sustained release of human calcitonin from thermosensitive block copolymer hydrogel10.1016/j.ijpharm.2017.05.006 ↗
35. The structure and mechanism of formation of human calcitonin fibrils10.1016/S0021-9258(18)53268-3 ↗
36. Metadynamics: a method to simulate rare events and reconstruct the free energy in biophysics, chemistry and material science10.1088/0034-4885/71/12/126601 ↗
37. A bias-exchange approach to protein folding10.1021/jp067873l ↗
38. On the accuracy of metadynamics and its variations in a protein folding process10.1080/08927022.2014.931680 ↗
39. Atomistic picture for the folding pathway of a hybrid-1 type human telomeric DNA G-quadruplex10.1371/journal.pcbi.1003562 ↗
40. A bias-exchange approach to protein folding10.1021/jp067873l ↗
41. Defining the molecular basis of amyloid inhibitors: human islet amyloid polypeptide-insulin interactions10.1021/ja504031d ↗
42. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit10.1093/bioinformatics/btt055 ↗
43. GROMACS: fast, flexible, and free10.1002/jcc.20291 ↗
44. PLUMED 2: New feathers for an old bird10.1016/j.cpc.2013.09.018 ↗
45. PLUMED: a portable plugin for free-energy calculations with molecular dynamics10.1016/j.cpc.2009.05.011 ↗
46. Improved side-chain torsion potentials for the Amber ff99SB protein force field10.1002/prot.22711 ↗
47. Bridging calorimetry and simulation through precise calculations of Cucurbituril-guest binding enthalpies10.1021/ct5004109 ↗
48. ACPYPE - AnteChamber PYthon Parser interface10.1186/1756-0500-5-367 ↗
49. Menschliches calcitonin VI1
50. Amyloids protect the silkmoth oocyte and embryo10.1016/S0014-5793(00)01888-3 ↗
51. Inhibitory effects of magnolol and honokiol on human calcitonin aggregation10.1038/srep13556 ↗
52. Quantification of apoptosis and necroptosis at the single cell level by a combination of Imaging Flow Cytometry with classical Annexin V/propidium iodide staining10.1016/j.jim.2015.04.025 ↗
53. Effects of silicon on osteoblast activity and bone mineralization of MC3T3-E1 cells10.1007/s12011-012-9593-4 ↗
54. Effects of continuous passaging on mineralization of MC3T3-E1 cells with improved osteogenic culture protocol10.1089/ten.tec.2012.0412 ↗
55. Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies10.1007/s11095-009-0015-z ↗
56. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy10.1016/S0022-3565(24)37553-6 ↗
57. Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Aeromonas hydrophila in Chinese soft-shelled turtles (Trionyx sinensis)10.1111/jvp.12214 ↗
58. Rare causes of hypercalcemia10.1210/jc.2005-0675 ↗
59. Cancer-induced hypercalcemia
60. Forty years of calcitonin-where are we now? A tribute to the work of Iain Macintyre10.1016/S8756-3282(02)00688-9 ↗